Pharmaceutical Delivery Technologies

Pharmaceutical delivery technologies encompass an array of strategies designed to transport therapeutic agents safely and effectively to their sites of action. Traditional approaches—oral tablets, injections and topical applications—have given way to sophisticated controlled-release, targeted and stimuli-responsive systems. Controlled-release platforms use polymers, lipids or inorganic matrices to maintain steady drug levels, reduce dosing frequency and enhance patient compliance. Targeted delivery exploits passive accumulation in leaky tissues or active recognition of cellular markers, thereby concentrating medication at diseased sites while minimising off-target effects. Stimuli-responsive carriers harness local cues—pH shifts, enzymes or temperature changes—to trigger on-demand release. Microfluidic synthesis, nanotechnology and bioinspired formulations have furthered precision manufacture of monodisperse nanoparticles, liposomes and hydrogels. These vehicles can encapsulate small molecules, peptides, proteins and nucleic acids, protecting labile cargos from degradation and modulating pharmacokinetics. As a result, new treatments for cancer, metabolic disorders, neurological conditions and inflammatory diseases have emerged, underpinned by rigorous in vitro–in vivo correlation models. Global challenges now include scalable manufacture, rigorous characterisation and regulatory alignment to ensure these advanced systems fulfil their clinical promise.

Research from Nature Portfolio

Innovations in hydrogel-anchored liposomal systems have demonstrated prolonged intra-articular residence and sustained peptide release for cartilage repair. In one study, teriparatide-loaded liposomes were anchored within a gallic-acid grafted gelatin hydrogel that forms in situ without impeding joint mobility, promoting chondrocyte proliferation and attenuating inflammatory signalling. Separately, continuous microfluidic vortex focusing has enabled scalable production of size-tunable liposomes down to 27 nm at throughputs exceeding 20 g h^–1, offering a single-step route to highly uniform vesicles for drug delivery. Complementing these advances, near-infrared-activatable biomimetic nanogels, camouflaged with apolipoprotein E-decorated erythrocyte membrane, cross the blood–brain barrier upon irradiation and release chemotherapeutic agents into deep glioblastoma lesions, demonstrating the potential of stimuli-responsive carriers for intracranial applications.

Research from all publishers

Outside of the Nature portfolio, pH-responsive polymeric nanoparticles co-loading paclitaxel and bicarbonate have been shown to release drug selectively in the acidic microenvironment of injured vessels, effectively inhibiting restenosis in preclinical models. In vascular therapies, red blood cell hitchhiking has emerged as a universal targeting strategy: nanoparticles adsorbed to erythrocytes transfer to the first downstream organ, boosting delivery by orders of magnitude to lungs or brain without haemolysis. For osteoarthritic joints, thermo-sensitive composite hydrogels incorporating platelet-rich plasma and antioxidant copper nanodots have achieved in situ gelation, scavenged inflammatory radicals and repolarised macrophages towards tissue repair, substantially reducing cartilage degradation in animal studies.

Pharmaceutical Delivery Technologies publication trend

The graph below shows the total number of articles in pharmaceutical delivery technologies across all publications each year (not limited to Nature Index journals).

Technical terms

Controlled release: A formulation approach that sustains drug release at a predetermined rate over an extended period to maintain therapeutic levels.

Passive targeting: Exploitation of anatomical and physiological features, such as the enhanced permeability and retention (EPR) effect in tumours, to accumulate nanoparticles at disease sites.

Stimuli-responsive carrier: A delivery vehicle engineered to release its cargo upon exposure to specific environmental triggers, including pH, temperature, enzymes or light.

Microfluidics: A manufacturing technique that manipulates fluids in microscale channels to achieve precise, reproducible synthesis of nanoparticles and liposomes.

Liposome: A spherical vesicle composed of one or more phospholipid bilayers, used to encapsulate hydrophilic or hydrophobic drugs for improved bioavailability and reduced toxicity.

Hitchhiking: A nanoparticle targeting strategy whereby particles adsorbed onto circulating cells (for example, erythrocytes) transfer to downstream vasculature, enhancing organ-specific delivery.

References

1. An Overview of Drug Delivery Systems.
2. An injectable liposome-anchored teriparatide incorporated gallic acid-grafted gelatin hydrogel for osteoarthritis treatment. Nature Communications (2023).
3. Microfluidic vortex focusing for high throughput synthesis of size-tunable liposomes. Nature Communications (2022).
4. Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma. Nature Communications (2022).
5. pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis. Pharmaceutics (2022).
6. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nature Communications (2018).
7. Multifunctional thermo-sensitive hydrogel for modulating the microenvironment in Osteoarthritis by polarizing macrophages and scavenging RONS. Journal of Nanobiotechnology (2022).